BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 21097437)

  • 1. [Weekly irinotecan plus capecitabine as a second-line chemotherapy for advanced gastric cancer: an analysis of 21 cases].
    Liu Y; Kang MF; Luo MQ; Dong CM
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Nov; 30(11):2575-6. PubMed ID: 21097437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
    Zhao WY; Chen DY; Qi Q
    Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):295-8. PubMed ID: 21575503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer.
    Luo HY; Wang ZQ; Wang FH; Qiu MZ; Teng KY; Ruan DY; He YJ; Li YH; Xu RH
    Am J Clin Oncol; 2011 Dec; 34(6):555-60. PubMed ID: 22101386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
    Cartwright T; Kuefler P; Cohn A; Hyman W; Berger M; Richards D; Vukelja S; Nugent JE; Ruxer RL; Boehm KA; Asmar L
    Clin Colorectal Cancer; 2008 Nov; 7(6):390-7. PubMed ID: 19036692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.
    Oh SC; Sur HY; Sung HJ; Choi IK; Park SS; Seo JH; Jeen YT; Chun HJ; Shin SW; Mok YJ; Kim JS; Kim YH
    Br J Cancer; 2007 May; 96(10):1514-9. PubMed ID: 17473829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer.
    Han JY; Lee DH; Kim HY; Kim EA; Lee JJ; Ju SY; Shin EH; Lee JS
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5909-14. PubMed ID: 14676114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.
    Brell JM; Krishnamurthi SS; Javle M; Saltzman J; Wollner I; Pelley R; Dowlati A; Kantharaj BN; Schluchter MD; Rath L; Ivy SP; Remick SC
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):851-7. PubMed ID: 18670776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer.
    Park SH; Bang SM; Cho EK; Baek JH; Oh JH; Im SA; Park YS; Shin DB; Lee JH
    Oncology; 2004; 66(5):353-7. PubMed ID: 15331921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study.
    Guimbaud R; Louvet C; Ries P; Ychou M; Maillard E; André T; Gornet JM; Aparicio T; Nguyen S; Azzedine A; Etienne PL; Boucher E; Rebischung C; Hammel P; Rougier P; Bedenne L; Bouché O
    J Clin Oncol; 2014 Nov; 32(31):3520-6. PubMed ID: 25287828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine and irinotecan in advanced gastric cancer.
    Sharma SP
    Lancet Oncol; 2007 Jul; 8(7):577. PubMed ID: 17668483
    [No Abstract]   [Full Text] [Related]  

  • 11. Irinotecan plus capecitabine as first-line chemotherapy in advanced colorectal cancer.
    Gennatas C; Michalaki V; Gennatas S; Papalambros E
    Anticancer Res; 2008; 28(3B):1923-6. PubMed ID: 18630482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
    Shin SJ; Ahn JB; Choi HJ; Cho BC; Jeung HC; Rha SY; Chung HC; Roh JK
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):75-81. PubMed ID: 17375304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan plus capecitabine as a second-line treatment after failure of 5-fluorouracil and platinum in patients with advanced gastric cancer.
    Sun Q; Hang M; Xu W; Mao W; Hang X; Li M; Zhang J
    Jpn J Clin Oncol; 2009 Dec; 39(12):791-6. PubMed ID: 19797415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer.
    Baek JH; Kim JG; Jeon SB; Chae YS; Kim DH; Sohn SK; Lee KB; Choi YJ; Shin HJ; Chung JS; Cho GJ; Jung HY; Yu W
    Br J Cancer; 2006 May; 94(10):1407-11. PubMed ID: 16641916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer.
    Hofheinz RD; Horisberger K; Woernle C; Wenz F; Kraus-Tiefenbacher U; Kähler G; Dinter D; Grobholz R; Heeger S; Post S; Hochhaus A; Willeke F
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1384-90. PubMed ID: 16979839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
    Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
    Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas.
    Lo SS; Khorana AA; Javle M; Simon S; Kiefer G; Rajasenan K; Wang H; Hantel A; Shayne M; Hwang J; Schmotzer A; Ramanathan RK
    Oncology; 2010; 78(2):125-9. PubMed ID: 20389134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results.
    Patt YZ; Lee FC; Liebmann JE; Diamandidis D; Eckhardt SG; Javle M; Justice GR; Keiser W; Salvatore JR; Bexon A; Lin E
    Am J Clin Oncol; 2007 Aug; 30(4):350-7. PubMed ID: 17762434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of low dose capecitabine combined to irinotecan in advanced and metastatic gastric cancer.
    Farhat FS; Kattan J; Chahine GY; Younes FC; Nasr FL; Mroue RM; Ghosn MG
    Med Oncol; 2010 Sep; 27(3):722-7. PubMed ID: 19644778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study.
    Kakolyris S; Souglakos J; Polyzos A; Ardavanis A; Ziras N; Athanasiadis A; Varthalitis I; Amarantidis K; Tsousis S; Vamvakas L; Vardakis N; Georgoulias V;
    Oncology; 2008; 74(1-2):31-6. PubMed ID: 18544957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.